Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders.
Adverse events
Dermatology
Dermatología
Eventos adversos
Inhibidores de JAK
Inhibidores de Janus kinasa
JAK inhibitors
Janus kinase inhibitors
Off-label
Safety
Seguridad
Journal
Actas dermo-sifiliograficas
ISSN: 1578-2190
Titre abrégé: Actas Dermosifiliogr
Pays: Spain
ID NLM: 0373062
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
07
04
2023
revised:
05
06
2023
accepted:
12
06
2023
medline:
5
10
2023
pubmed:
19
6
2023
entrez:
18
6
2023
Statut:
ppublish
Résumé
JAK inhibitors target specific inflammatory cytokines involved in various inflammatory diseases. Four molecules have been approved for dermatological use: upadacitinib, baricitinib, abrocitinib and topical ruxolitinib. Off-label prescriptions for other dermatological conditions have been reported. We conducted a narrative review of the literature to assess the long-term safety profile of currently approved JAK inhibitors in dermatology, and their off-label use in skin disorders. We performed literature searches with Pubmed and Google Scholar from January 2000 to January 2023, using the keywords "Janus kinase inhibitors", "JAK inhibitors", "off-label", "dermatology", "safety", "adverse events", "ruxolitinib", "upadacitinib", "abrocitinib" and "baricitinib". Our search yielded a total of 37 dermatological disorders with studies supporting the use of these JAK inhibitors. Preliminary studies indicate that JAK inhibitors generally have a favorable safety profile and can be considered as an option in many dermatological disorders.
Identifiants
pubmed: 37331618
pii: S0001-7310(23)00496-9
doi: 10.1016/j.ad.2023.06.012
pii:
doi:
Substances chimiques
Janus Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
784-801Informations de copyright
Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.